Condition: Beta-Thalassemia · Sponsor: Celgene
This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric participants with β-thalassemia. The study will be conducted in 2 parts for both transfusion-dependent (TD) and non-transfusion-dependent (NTD) β-thalassemia participants: TD Part A will be in adolescent participants aged 12 to \<18 years with two dose escalation cohorts, followed by a dose expansion cohorts. NTD Part A will be conducted in the same age group participants as TD Part A with dose confirmation and expansion cohorts. After Part A TD participants have completed at least one year of treatment, all available safety data from Part A adolescent participants will be evaluated before initiating TD and NTD Part B in the age group from 6 to \<12 years old. Part B will consist of two dose escalation cohorts for TD and two dose escalation cohorts for NTD. Upon completion of the Treatment Period, participants of any cohort who are benefiting from the study treatment, will be offered the opportunity to continue luspatercept treatment in the Long-term Treatment Period for up to 5 years from their first dose. Participants who discontinue study treatment at any time will continue in the Posttreatment Follow-up Period for at least 5 years from their first dose of luspatercept, or 3 years from their last dose, whichever occurs later, or until they withdraw consent/assent, are lost to follow-up, or the End of Trial, whichever occurs first. If neither commercial treatment nor an…
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 601 | Los Angeles, California, United States | Completed |
| New York Presbyterian Hospital | New York, New York, United States | Recruiting |
| Southern Medical University Nanfang Hospital | Guangzhou, Guangdong, China | Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| People's Liberation Army The 923rd Hospital | Nanning, GX, China | Recruiting |
| West China Hospital - Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-Sen University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, China | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Recruiting |
| Universitatsklinikum Ulm | Ulm, Germany | Recruiting |
| General Children's Hospital "Agia Sophia" | Athens, Greece | Recruiting |
| Kamala Hospital and Research Center | Hyderabad, Andhra Pradesh, India | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04143724